Endometriosis Patients Undergoing Quinagolide Treatment
Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA (Other)
Overall Status
Completed
CT.gov ID
NCT00625950
Collaborator
(none)
5
1
3
1.7
Study Details
Study Description
Brief Summary
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
5 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.
Study Start Date
:
Feb 1, 2008
Actual Primary Completion Date
:
Apr 1, 2008
Actual Study Completion Date
:
May 1, 2008
Outcome Measures
Primary Outcome Measures
- observation of three month treatment with Quinagolida in endometriosis patients [onset and three months after onset]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 37 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Hyperprolactinemia
-
Unexplained infertility
-
Endometriosis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Instituto Valenciano de Infertilidad | Valencia | Spain | 46015 |
Sponsors and Collaborators
- Instituto Valenciano de Infertilidad, IVI VALENCIA
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00625950
Other Study ID Numbers:
- VLC-AP-10208-208-1
First Posted:
Feb 29, 2008
Last Update Posted:
Jan 12, 2009
Last Verified:
Jan 1, 2009
Keywords provided by ,
,
Additional relevant MeSH terms: